Media about us

• Syndax readies its 2nd IPO attempt during a market tempest

  24 February 2016 John Carroll / FierceBiotech

  

  Looking to cash in on its eventful past year, Syndax is upping its bet on a turbulent market with an IPO that will seek to garner about $66 million. The last time Syndax made a try at an IPO, it set out for a $60 million windfall. But this time, it's looking to trade on the rep of its new, high-profile CEO--AstraZeneca vet Briggs Morrison--and a string of partnerships with a who's who in immuno-oncology by selling 4.4 million shares at $14 to $16 per share. At most, it could gain up to $70 million, though the odds against a top-of-the-range response are intimidating.

• Groundbreaking STI test can detect chlamydia in 30 minutes

  19 February 2016 The Telegrah / Lifestyle

  

  The Atlas io system was created by the University of Bath's spin-off biotech company Atlas Genetics in 2005. It has now won approval from the EU to be sold. The development means that patients can be tested and treated for the disease within a single clinic visit.

• University of Bath biotech spin-out wins EU approval for ground-breaking chlamydia test

  08 February 2016 Julia Bradshaw / The Telegraph

  

  A small biotech that started life at the University of Bath has won approval from European regulators to sell a device that tests for the sexually transmitted disease chlamydia in just 30 minutes.

• Blood Test Offers An Amazing View Of Metastatic Prostate Cancer Cells

  04 February 2016 Elaine Schattner / Forbes

  

  A few months ago, I met with Murali Prahalad, CEO of Epic Sciences (San Diego). We discussed the company’s methods of processing blood samples to store, identify and examine circulating tumor cells (CTCs). Since then I’ve been following reports on Epic’s method and other, competing CTC platforms.

• Biomarker Discovery Gets a Fix on Cancer

  01 February 2016 Cancer Kathy Liszewski / Genetic Engineering & Biotechnology News

  

  ust as signposts provide information, direction, and guidance, so too cancer biomarkers can better reveal the complex, dynamic, and heterogeneous landscape of malignancies. Such information is critical for creating better cancer diagnostics, prognostics, and therapeutics, but the journey to find just the right biomarker is often a long and winding road.

• Subscribe to Cancer Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

  28 January 2016 GenomeWeb

  

  Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

• Epic Sciences, Station X Link Up to Analyze CTC Data for CDx Development

  25 January 2016 GenomeWeb

  

  Epic Sciences has announced it will use Station X's GenePool platform as part of data analysis for its collaborations with pharmaceutical companies to develop circulating tumor cell-based companion diagnostics.

• Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration

  22 January 2016 Business Wire

  

  Georgia Bio announced its 2016 Deals of the Year for pharmaceutical, biotechnology, healthcare IT and medical device companies in the following categories – private financing, joint ventures, initial public offering, mergers, acquisitions and economic development – reflecting a broad range of activity. The annual Deal of the Year awards recognize transactions by life sciences companies in Georgia such as financings, partnering agreements and government grants that are significant to the state’s industry development.

• Never leave a cell behind

  20 January 2016 Lori Lesko / Cancer Research News, DDNews

  

  Targeted toward cracking the code to treating disease resistance in tumor changes, Epic Sciences Inc. has partnered with the Penn Medicine Abramson Cancer Center on multiple studies to explore biomarkers, identified by the analysis of circulating tumor cells (CTCs) at a single-cell resolution. This process is predictive of response to personalized cancer therapeutics—and a precursor to the future of oncology.

• Companion Diagnostics Evolve

  19 January 2016 Chelsea Lacey-Mabe / Advanced healthcare Network

  

  Out of seven billion people on this earth, no two people are the same. Companion diagnostics (CDx) providers argue their medicines shouldn't be the same either. In a world where someone can customize their sandwich, sneakers and even their physical appearance, the healthcare industry has realized one-size-fits-all treatments are no longer a good fit.